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Conclusions: A modest surgical interval prolongation more 
than 6 weeks was safe, did not negatively affect response or 
oncologic outcomes and was identified as independent 
favourable prognostic factor for overall survival. Randomized 
studies are justified to explore more significant delayed time 
intervals between neoadjuvant CRT and surgery in LARC. 
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Purpose/Objective: To evaluate retrospectively efficacy and 
toxicity of adjuvant radio-chemotherapy in patients with 
gastric cancer and to relate these results to the outcome of 
landmark INT0116 study that was criticized because of high 
toxicity and poor treatment compliance. 
Materials and Methods: A total of 102 patients, who 
underwent postoperative fluorouracil (5-FU)-based radio-
chemotherapy in our institution between 2004 and 2010 for 
stage IB-IV (AJCC 6th ed.) gastric cancer were selected. Stage 
distribution was as follows: IB-5 (5%), II-32 (31%), III-49 (48%), 
and IV-14 (14%). There were 96% R0 resections; 15% of the 
patients had a D2 resection. Radiotherapy to 45Gy was 
defined individually and delivered with 3D conformal 
technique. Chemotherapy was carried out during the first 
four and last three days of RT with continuous infusion of 5-
FU (400mg/m2/day) and Leucovorin. Patients received 
additional three cycles of chemotherapy of 5-
FU(425mg/m2/d), one before and two after radio-
chemotherapy. Acute hematological and gastro-intestinal 
toxicity was evaluated according to the CTC v3.0 scale. 
Results: Seventy-four (72.5%) and 98 (96%) patients received 
all five planned cycles and completed radiotherapy, 
respectively. The 3- and 5-year overall survival (OS) rates 
were 57% and 48%, respectively. Multivariate analysis showed 
that variables significantly affecting OS were pT3-T4, pN2-3, 
R1 resection and female. Only 2% of patients experienced 
grade 3 gastro-intestinal toxicity; 7% had grade 3 or higher 
hematological toxicity. 
Conclusions: We demonstrated improved treatment 
tolerance, compliance, OS of adjuvant radio-chemotherapy 
for gastric cancer in comparison with INT0116 study. 
Conformal radiation techniques might have contributed to 
this improvement.  
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Purpose/Objective: Preoperative radiation therapy combined 
with fluoropyrimidine is the standard treatment for locally 
advanced rectal cancer. However, there is a large individual 
difference or variation in tolerance and therapeutic 
efficiency. The genetic polymorphisms represent one of the 
major causes in this variation. The aim of our study is to 
analyze the relationship between gene polymorphism of the 
Methylenetetrahydrofolate reductase 'MTHFR' (important 
enzyme in floropyrimidine metabolism) tolerance and the 
therapeutic efficiency of fluoropyrimidine in patients with 
locally advanced rectal cancer. 
Materials and Methods: Between December 2011 and 
November 2013, 52-blood samples were realized for DNA 
extraction, MTHFR gene polymorphism were determined by 
polymerase chain reaction restriction fragment length 
polymorphism PCR-RFLP in patients with stage II and III 
histologically proved rectal cancer there were 21 women and 
31 men with a median age 50.8 years, range 23-70 years. The 
tumor was located in lower rectum in 56% of cases. 30 
patients had stage III. Preoperative radiation therapy was 
delivered in all patients with a total dose of 45 Gy, 
associated at fluoropyrimidine (5Fluorouracil + folic acid in 
30 patients, Capecitabine in 22 patients), followed by 
surgical resection in eight weeks in all patients. The 
treatment tolerance was evaluated according to the NCI-CTC 
version 3 toxicity criteria. Therapeutic efficiency was 
evaluated by histopathological postoperative specimen 
examination. Kaplan-Meyer survival curves were defined for 
each polymorphism in our series. 
Results: The distribution of the three genotypes CT, CC and 
TT were respectively (32.6%, 48% and 19.2%). The risk of 
developing severe (grade 3-4) toxicity was observed in 677 CC 
(9,6%), 677CT(7,6%) and 677TT (3,8%). T-level downstaging 
after neoadjuvant treatment was demonstrated in 63.3% of 
cases in patients with 677TT genotype, it was 40% in 677CT 
genotype and 58.8% in 677CC genotype. No association is 
observed between C677T polymorphism and survival (log 
rank= 0.02, p = 0.99). 
Conclusions: In spite of the limited patient number, our 
study shows that the MTHFR 677 TT genotype can have a 
protective role of fluoropyrimidine toxicity, and it can be a 
predictive factor in therapeutic efficiency. This study will be 
continued, in order to include more patients and to analyze 
the second polymorphism in MTHFR gene (1298 A>C). 
   
 
 
 
 
